UW researchers have created a biological therapeutic that stimulates the immune system to fight solid tumors. The researchers fused the cytokines IL-6 and IL- together to form a bifunctional biomol...
Learn More

UW researchers have identified a molecule commonly used as a vaccine adjuvant to add to the combination of radiation therapy and checkpoint inhibitor treatment to drive the immune system’s response ...
Learn More

UW researchers have identified a molecule commonly used as a vaccine adjuvant to add to the combination of radiation therapy and checkpoint inhibitor treatment to drive the immune system’s response ...
Learn More

UW-Madison researchers have developed a novel approach for enhancing pyroptosis, which could prove beneficial in treating cancer. The inventors combine intracellular delivery of gasdermin with a small...
Learn More

Theranostics, a term derived from a combination of therapeutics and diagnostics, is an emerging field of medicine where specific radionuclide disease-targeting agents are used to diagnose and treat me...
Learn More

The present technology from UW Madison inventors provides nanoparticles comprising a positively charged polymer (e.g., polylysine) electrostatically bound to iron oxide nanoparticles and CpG oligodeox...
Learn More

The present invention by UW Madison researchers provides combination therapies and methods of treating cancer, including, cancers that are resistant to PD-1 therapy. The combination therapies describe...
Learn More

Ex vivo expansion and activation of T cells are prerequisites for any form of genetically engineered T cell immunotherapy. Several expansion and activation methodologies have been developed. However, ...
Learn More

Use of viral vectors for chimeric antigen receptor (CAR) T cell manufacturing constitutes a bottleneck in the supply chain for biomanufacturing and can be problematic due to: (1) batch-to-batch variab...
Learn More

UW-Madison researchers have developed a nanoparticle-based platform comprising targeting agents (i.e., tumor selective peptides) and active agents (e.g., immuno- and chemo-drugs).  The nanopartic...
Learn More

The present invention from UW Madison researchers provides in vitro derived a multicell conjugate comprising an iNKT cell and a dendritic cell (DC). The invention also provides methods of making the m...
Learn More

Currently there are no cell therapies approved for use against acute radiation injury (ARS). Severe ARS can cause death and the only cell treatment is allogenic bone marrow transplantation (BMT). Unfo...
Learn More

This invention provides methods for modulating cellular gene expression for genes operably linked to an NRSE element that is recognized by an NRSF transcriptional repressor, by changing the concentrat...
Learn More

Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be u...
Learn More

The inventors have discovered that certain alkylphosphocholine analogs are preferentially taken up by multiple myeloma tumor cells, as compared to non-tumor cells. The inventors have further demonstra...
Learn More

Peptides derived from amino acid residues 210 to 240 of human syndecan 1 and methods of use of such peptides are described. These peptides can inhibit activation of α4β1 integrin (also known as very...
Learn More

The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are admi...
Learn More

Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of β-hairpin peptides conjugated thereto. Also included are pharmaceutical compositions and meth...
Learn More

Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; ...
Learn More

The present disclosure provides compositions, methods and kits for the treatment of cancer. Particularly, the present disclosure provides synergistic compositions comprising at least one cytotoxic rib...
Learn More

The present invention relates to novel compounds which are aryl hydrocarbon receptor (AHR) ligands and uses thereof. Methods of activating the AHR receptor in a subject are also provided. The compound...
Learn More

Disclosed are methods, kits, polypeptides, and pharmaceutical compositions for inducing an immune response in a subject, which may include a T-cell mediated immune response. The methods comprise admin...
Learn More

The present technology relates generally to oligolactic acid conjugates of paclitaxel, rapamycin, selumetinib, and other anticancer agents, micelle compositions containing such conjugates and methods ...
Learn More

Described herein are methods of expanding a population of hematopoietic stem cells by contacting the population of hematopoietic stem cells with an effective amount of an inhibitor of G-protein couple...
Learn More

A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound tha...
Learn More